Assessing parallelism using Parallel Line Analysis (PLA) in MARS
Screening for drug compounds with higher potency is of keen interest for many pharmaceutical drug development departments. Finding compounds which lead to the same response as a reference substance but at a lower dose can be the key to lower the risk of side-effects and to lower manufacturing costs. Parallel line analysis (PLA) is often applied in this context in order to prove parallelism of the underlying dose-response curves and subsequently estimate the relative potencies of substances compared to a reference substance. Here we describe how to apply PLA in BMG LABTECHs MARS data analysis software to inhibitor binding data to assess binding potencies of Prostaglandin D synthase inhibitors.
Using PLA, the (relative) binding potency of the hematopoietic prostaglandin D synthase inhibitor TFC 007 was estimated to be about 300-fold higher than that of the well-characterized HQL-79 imhibitor.